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Considering the increasing concern
regarding the development of drug
resistance, the use of pharmacology-
based information is critical to design
successful strategies for future hel-
minth parasite control in livestock.
Integrated pharmacokinetic/pharma-
codynamic and clinical pharmacology
knowledge is required to preserve both
well-established and modern
anthelmintics.Anthelmintic resistance in human and animal pathogenic helminths has been
spreading in prevalence and severity. Multidrug resistance is a widespread
problem in livestock animals. The use of available pharmacology-based infor-
mation is critical to the design of successful future approaches for parasite
control. Relevant scientific work supporting the main strategies to optimize
anthelmintic therapy in ruminants under the current drug-resistance scenario is
described here. We emphasize the need for further integrated pharmaco-
parasitological knowledge to extend the lifespan of both traditional and novel
anthelmintic compounds, and to progress in the identification of complemen-
tary/alternative measures of parasite control in livestock animals.Assessment of drug disposition in the
host and comprehension of the
mechanisms of drug influx/efflux/detox-
ification in different target helminths,
have signified relevant progress in
anthelmintic therapy in ruminants.
Different pharmacokinetic-based
approaches to enhance parasite expo-
sure (pharmacokinetic optimisation)
and the use of a mixture of molecules
from different chemical families (drug
combinations) have been assessed as
valid strategies to control resistant
parasites and to slow the selection
for further resistance.
Identification/development of comple-
mentary and/or alternative (i.e., bioac-
tive phytochemicals) measures seems
critical to achieve sustained parasite
control in livestock.
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(C. Lanusse).Resistance-Related Failures in Anthelmintic Therapy
Nematode parasites of ruminants account for one of the largest infectious disease prob-
lems in grazing livestock systems worldwide. Despite promising research results, non-
chemical control approaches are not yet available for routine commercial use, and parasite
control in livestock still relies on the use of synthetic antiparasitic drugs, which comprise the
largest sector of the animal pharmaceutical industry [1]. The integration of available
information on the host–parasite–environment relationship, with the understanding of
the pharmacological properties of existing drugs, has contributed to more efficient parasite
control. The excellent broad-spectrum efficacy, good tolerability, and low costs of the
available synthetic anthelmintic drugs (see Glossary) have accounted for their extended
use in livestock animals during the last 50–60 years. However, the over-reliance on
anthelmintics and their inadequate use has led to therapeutic failures and to the widespread
development of parasite resistance.
Most fields of chemotherapy benefit from in vitro test systems that can be used to accurately
predict drug concentrations required for efficacy in vivo. It has been difficult to develop a culture
system for nematodes to determine in vitro potency for anthelmintics [2]. This inconvenience, a
key limitation in estimating the active drug concentration required to achieve optimal in vivo
activity, has hindered further development in the field. However, the progress made on our
comprehension of the pharmacokinetic and pharmacodynamic mechanisms of drug
action has been sufficient to achieve a deep understanding of the pharmacology of the main
chemical families. The time of parasite exposure to adequate levels of active drug determines
the efficacy and/or persistence of activity for most of the anthelmintics used in ruminants
(Box 1). The therapeutic failures due to the widespread development of multiresistant nema-
tode parasites affecting livestock animals pose a huge scientific challenge. Here we review the
main available valid pharmacological strategies to optimize control under a complex multidrug-
resistance situation (Figure 1, Key Figure).664 Trends in Parasitology, August 2018, Vol. 34, No. 8 https://doi.org/10.1016/j.pt.2018.05.005
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Glossary
Anthelmintics: benzimidazoles,
imidazothiazoles (levamisole),
macrocyclic lactones, salicylanilides
(closantel), tetrahydropyrimidines
(morantel, pyrantel),
organophosphates (coumaphos,
naphthalophos, etc.) and the novel
spiroindole (derquantel) and
aminoacetonitrile derivatives
(monepantel), are the main chemical
families of synthetic anthelmintics
used to control nematode infections
in ruminants.
Benzimidazoles: the benzimidazole
methylcarbamates albendazole,
fenbendazole, and their sulphoxide
derivatives are among the most
extensively used anthelmintics. They
are active against larval/adult stages
of gastrointestinal (GI) and lungworm
nematodes, eggs (ovicidal) and
tapeworms. Triclabendazole is the
main available flukicidal drug, active
against immature and mature liver
flukes.
Bioactive phytochemicals: these
are a variety of plant-derived (natural)
compounds with different therapeutic
activities. The terpenes, condensed
tannins, and flavonoids are among
the natural products with well
demonstrated anthelmintic activity.
Drug combination treatment: this
is defined as the use of two or more
anthelmintic drugs with a similar
spectrum of activity and different
mode of action/resistance to treat a
single disease (i.e., GI parasitism).
Drug-metabolizing enzymes:
phase 1 (oxidative, reductive,
hydrolytic) or phase 2 (conjugative)
enzymes devoted to the
biotransformation of endo- and
xenobiotics, including therapeutically
used drugs.
Drug systemic exposure: the total
drug availability in the body
expressed as the AUC (area under
the drug/metabolite concentration–
time curve). AUC is proportional to
the total amount of drug absorbed.
Drug-transport proteins: ATP-
binding cassette (ABC) transporters
are transmembrane proteins found in
all living organisms. They are
responsible for the ATP-dependent
transport of a wide variety of drugs,
lipids, and metabolic products across
the plasma membrane and
intracellular membranes. P-
glycoprotein (P-gp) is the most well
Box 1. Pharmacokinetic Principles Supporting Drug Anthelmintic Activity
The overall pharmacokinetic process, including drug absorption, tissue distribution, and its biotransformation/elimina-
tion pattern, is crucial for allowing the drug to reach the target parasites located in different tissues at sufficient
concentrations/time to exert its anthelmintic effect (Figure I). There is a strong relationship between pharmacokinetics
(which determine drug exposure at the parasite location site) and pharmacodynamics (drug effect). Dissolution of drug
particles in gastrointestinal (GI) fluids is a particularly important phenomenon for drugs administered as suspensions by
the oral route (such as benzimidazole compounds, morantel/pyrantel, etc.). Dissolution is a crucial step because drug
particles must dissolve in the enteric fluids in order to allow absorption through the GI mucosa and/or penetration
through the external surface of helminth parasites located in the digestive tract [99]. The undissolved drug particles
passing down the GI tract in the luminal content are excreted in feces without exerting its action. Anthelmintic
compounds formulated as drug solutions for parenteral injection in domestic animals (macrocyclic lactones, levamisole,
etc.) do not require dissolution before systemic absorption. In those cases, the digestive secretion process (i.e.,
abomasal secretion) is an important step to assure drug–nematode contact. Drug absorption is a main limiting factor
that determines the amount of drug reaching the systemic circulation (systemic exposure). The reversible exchange
between the bloodstream and tissues allows the drug and/or metabolites to achieve concentrations that are anthel-
mintically active at the tissues of parasite location [99].
Drug entry and accumulation into target helminths are critical issues to achieve optimal efficacy. Both in vivo and ex vivo
studies have shown that transcuticular/tegumental diffusion is a relevant pathway for drug entrance into helminths
(including blood-sucking parasites), which is dependent on lipophilicity as a major physicochemical determinant of drug
capability to reach therapeutic concentrations within the parasite [100]. It is evident that drug entry into a helminth
parasite is crucial to achieve sufficient drug concentration at the site of action to exert the anthelmintic action. However,
the accumulation of active drug at the site of action will depend on the balance among drug entry (influx), the parasités
capacity to inactivate the drug metabolically, and drug efflux mediated by transporter proteins [101]. The time of parasite
exposure to active drug concentrations determines the efficacy and/or persistence of activity for most of the
anthelmintics used in ruminants. Altogether, these different factors will determine the final anthelmintic activity, as
is shown schematically in Figure I.
AnthelminƟc
acƟvity  
Depends on… 
Drug concentraƟons at the site
of parasite locaƟon
Time of parasite exposure
Mechanisms of drug acquisiƟon
by target parasites
The fate of the drug/metabolites within the
target parasites (influx–efflux balance)
Figure I. Key Pharmacological Issues on Which Anthelmintic Activity Depends.Pharmacokinetic-Based Optimization of Drug Activity
Absorption-Related Enhancement of Drug Systemic Availability and Target Parasite
Exposure
Pharmacokinetic processes directly influence the drug concentration level attained at the site of
action and the resultant pharmacological effect (Box 1). The main pathogenic parasites
affecting domestic animals and humans live in predilection sites, where food/energy from
the host can be easily obtained, such as the gastrointestinal (GI) lumen and mucosa, liver, bile
duct, lung, and skin. Anthelmintic drugs require effective concentrations attained at those sites
of parasite location for a certain period. The physicochemical properties and pharmacokinetic
disposition of these drugs have a direct influence on their anthelmintic activity [3] (Box 1). Due to
the great difficulties associated with developing new anthelmintic molecules, optimization of the
existing compounds has been a high priority for research in the field. A main strategy to optimizeTrends in Parasitology, August 2018, Vol. 34, No. 8 665
studied ABC transporter which is
able to pump a broad range of
structurally and functionally unrelated
compounds out of the cell (efflux
process). P-gp is widely distributed
in mammalian tissues and is
associated with a phenotype of
multidrug resistance to anticancer,
antimicrobials, and anthelmintic
drugs.
Macrocyclic lactones: the
avermectins (abamectin, ivermectin,
doramectin) and milbemycins
(moxidectin) are closely related 16-
membered macrocyclic lactones,
active at extremely low (0.2 mg/kg)
dosages against endo- and
ectoparasites (endectocides). The
long persistence of the broad-
spectrum anthelmintic activity against
adult and immature nematodes is
supported by their extensive tissue
distribution and prolonged residence
in the digestive mucosal tissue.
Parasite exposure: refers to the
amount of drug accumulated within a
target parasite as a result of the drug
influx–detoxification–efflux balance.
Pharmacodynamics: the response
of the body to the drug, including the
characterization of the drug–receptor
interaction. Pharmacodynamics deals
with the mechanism(s) of drug
action.
Pharmacodynamic interactions:
interactions occurring when one drug
may alter the intensity of the
pharmacological effects of another
drug when given concurrently. Drug-
to-drug interactions can lead to both
enhanced (additive or synergic
effects) and diminished (antagonism)
drug responses. Additive: the
combined activity of two drugs
equals the sum of their independent
activities measured separately.
Synergism: the combined effects of
two active ingredients are
significantly greater than their
independent effects. Antagonism: the
combined effect is lower than the
sum of effects induced by each
individual drug.
Pharmacokinetics:
pharmacokinetics involves the time
course of drug absorption,
distribution, metabolism, and
elimination from the host, which, in
turn, determines the concentration of
the active drug reaching both the site
(tissue) of parasite location and the
target worm.the use of existing anthelmintic drugs has been focused on the pharmacokinetic-based
enhancement of parasite exposure, which is now a well established pharmacological tool
to optimize anthelmintic therapy and delay the development of anthelmintic resistance. A
Monte-Carlo simulation of resistant-gene frequencies following treatment has indicated that
low and/or variable (erratic) worm exposure to the active drug accounts for the increased
frequency of resistance genes within a population [4]. Several pharmacological strategies
allowing the enhancement of drug systemic exposure (availability) and parasite exposure
have been deeply investigated and extensively reviewed in the literature. Alternative pharma-
ceutical approaches to improve drug formulations and management of animal feeding (fasting
and feed restriction) have been extensively studied as alternatives to improve the poor/erratic GI
absorption and to enhance the systemic exposure of the widely used broad-spectrum benz-
imidazole anthelmintics (Box 2). The chosen route of drug administration may also play a
relevant role in optimizing systemic exposure and efficacy of the highly lipophilic macrocyclic
lactone endectocide compounds against resistant nematodes in different animal species
(Box 2). Additionally, the evaluation of increased drug dosage levels has shown that accumu-
lation within target parasites is directly related to the drug concentration available in the
environment where the nematodes are located. Increasing drug exposure may be a useful
strategy for killing heterozygous resistant parasites present during the earliest phases of
resistance development [5] (Figure 1).
The complex interactions among drug physicochemical properties, pharmaceutical prepara-
tions, routes of administration and dose rate directly influence the resultant kinetic behavior and
the therapeutic efficacy of the different antiparasitic drugs (Box 2). Integrated understanding of
these pharmacological properties and the development of new formulations assuring increased
parasite exposure to the active drug may help to avoid misuse and prolong the lifespan of the
existing or novel anthelmintics.
Modulation of Drug-Metabolizing Enzymes
Anthelmintic drugs are biotransformed by different drug-metabolizing enzymes from both
hepatic and extrahepatic tissues. Metabolic conversions usually alter the polarity of the
anthelmintic parent molecule and, consequently, the way in which the drug is distributed
and excreted from the body. In vivo interference with the activity of certain drug-metabolizing
enzymes may give rise to pronounced modifications to both the pharmacokinetic behavior and
the therapeutic outcome of active anthelmintic molecules. Modulation/inhibition of the meta-
bolic activity may contribute to enhance the systemic exposure of active anthelmintic drugs
(Box 3). This rationale was pursued in a number of investigations assessing the pharmacoki-
netics and efficacy of benzimidazole compounds. Their intrinsic anthelmintic action, based on
the disruption of basic cell functions depending on the integrity of the microtubule system,
requires their sustained presence at the site of parasite location [6]. Consequently, extension of
the residence time of active benzimidazole molecules in the bloodstream is relevant for their
efficacy. Since these compounds are extensively metabolized in the liver, the inhibition of
certain metabolic pathways may have a relevant impact on their anthelmintic efficacy. In this
regard, parent thioether benzimidazoles, such as albendazole, fenbendazole, and triclaben-
dazole, undergo a two-step S-oxidation that renders sulphoxide and sulphone metabolites.
Mixed-function oxidases belonging to flavin-monooxygenase (FMO) and cytochrome P450
(CYP) families were found to be involved in the hepatic S-oxidation of these drugs in ruminants
[7,8]. In terms of parasite uptake/accumulation [9] and mode of action (binding to tubulin) [10],
parent thioethers are more efficient than their respective S-oxidized metabolites. Compared to
their parent drugs, sulphoxide metabolites have less anthelmintic potency, and sulphones are
virtually inactive. Indeed, oxidative metabolism in the liver results in a considerable reduction of666 Trends in Parasitology, August 2018, Vol. 34, No. 8
Pharmacokinetic interactions:
occur when a drug compound
modifies the pharmacokinetic
behavior of a second drug. As a
consequence, active drug
concentrations at the site of action
may be either increased (positive
interaction) or decreased (negative
interaction).
Refugia: the parasite population
‘escaping’ or ‘not exposed’ to the
anthelmintic treatment (i.e., free-living
stages in the environment at the time
of treatment).
Box 2. Absorption-Mediated Enhancement of Target Parasite Exposure to the Active Drug
Different drug-absorption-related approaches addressed to enhance parasite exposure have been proposed as valid
strategies to improve anthelmintic efficacy.
1. Improved Drug Formulations
Poor/erratic gastrointestinal (GI) absorption hinders the clinical efficacy of benzimidazole compounds. Different phar-
macotechnical strategies have been assayed to overcome their lack of water solubility (Table I). Amphiphilic surfactants
improved the absorption and systemic availability of albendazole metabolites in cattle [102]. Complexation with
cyclodextrins markedly increased the plasma availability of flubendazole metabolites in mice and pigs [103,104]
compared to a conventional suspension. Similarly, cyclodextrin-based solutions [103,105,106], solid dispersions
[107], and lipid nanocapsules [108] (Table I) have been used to enhance albendazole absorption, improving the
systemic exposure of its active sulphoxide metabolite.
2. Animal Feeding
Considering that low abomasal pH facilitates the dissolution of benzimidazole particles, fasting and/or reducing feed
intake prior to their oral administration drastically enhance drug absorption and systemic exposure of active metabolites
in sheep and cattle [109–111] (Table I). The delayed rate of passage of the drug down the digestive tract observed in
fasted animals accounted for increased dissolution (abomasum) and enhanced intestinal absorption, which correlated
with a marked enhancement in drug concentrations recovered from the digestive tract and tissues [109]. Those feed-
management-related therapeutic advantages are nowadays extensively used under field conditions.
3. Route of Administration
Oral administration accounted for markedly higher ivermectin concentrations recovered at the GI contents in compar-
ison to the parenteral treatment, which was reflected in enhanced drug accumulation within Haemonchus contortus
collected from treated sheep and improved efficacy [112] (Table I). The advantage of the oral route has also been
demonstrated for other macrocyclic lactones in cattle [58,113]. Only when worms with reduced susceptibility are
predominant can an improved efficacy for the oral treatment be observed. Enhanced drug exposure of resistant worms
located at the lumen of the abomasum/small intestine may account for that therapeutic advantage.
4. Dosage Levels
Increases in the effective dose rate for ivermectin and moxidectin (double dose) and albendazole (triple dose) in sheep
have accounted for enhanced drug exposure at the tissues of parasite location, as well as for improved drug
accumulation within a highly resistant H. contortus isolate collected from treated animals [114–116] (Table I). Although
useful from an experimental point of view, the risk of an extensively wide recommendation for the use of high dosages in
livestock practice may be associated with the selection of highly resistant nematodes, and to the adverse impact of the
presence of drug residues in edible tissues.
Table I. Approaches Investigated to Enhance the Absorption and Systemic Availability of Anthelmintic
Drugs in Different Animal Species
Approach Anthelmintic
drug
Animal
species
Pharmacokinetic
modification
Changes in therapeu-
tic response
Refs
Modified drug formulation
Amphiphilic
surfactants
ABZ Cattle Up to 164% increase
in AUC
NA [102]
Cyclodextrin FLBZ Mice 27-fold AUC
increase
Reduction of the
Equinococcus
granulosus cysts weight
7-fold greater than the
suspension treatment
[103]
FLBZ Pigs 6.6-fold AUC
increase
NA [104]
Solid dispersions ABZ Mice 1.5-fold AUC
increase
NA [107]
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Table I. (continued)
Approach Anthelmintic
drug
Animal
species
Pharmacokinetic
modification
Changes in therapeu-
tic response
Refs
Lipid nanocapsules ABZ Mice 2.2-fold AUC
increase within
hydatid cysts
collected from
infected mice
Efficacy increase (from
47% to 91%) against
hydatid cysts
[108]
Animal feeding management
Reduced feed intake OFZ Sheep 1.6-fold AUC
increase
Efficacy increase (from
60 to 94%) against
resistant Haemonchus
contortus
[110]
Full fasting prior to
treatment
ABZ Cattle 2-fold AUC increase.
Marked
enhancement of
drug exposure at the
GI tract
NA [109]
ABZ Sheep 1.6-fold AUC
increase. Marked
enhancement of
drug exposure at the
GI tract
Efficacy increase (from
74 to 90%) against
resistant H. contortus
[111]
Routes of administration
Oral versus
subcutaneous
treatment
(therapeutic dose
rates)
IVM Sheep 14-fold increase in
drug concentrations
within adult H.
contortus
Efficacy increase (from 0
to 40%) against IVM-
resistant H. contortus
[112]
IVM Horses NA Efficacy increase (from
36 to 100%) against adult
cyathostomins
[118]
MXD Cattle NA Efficacy increase (from
55 to 91%) against IVM-
resistant Cooperia spp.
[113]
Dosage levels
ABZ at 15 mg/kg (3
times the dose)
ABZ Sheep 7-fold ABZSO
plasma AUC
increase
Efficacy increase (from
16 to 59%) against highly
resistant H. contortus
[114,117]
IVM at 1 mg/kg (5
times the dose)
IVM Sheep 5-fold plasma AUC
increase
Efficacy increase (from
42 to 75%) against highly
IVM-resistant H.
contortus
[115]
MXD at 0.4 mg/kg
(double dose)
MXD Sheep 2.44-fold increase of
drug accumulation
within adult H.
contortus
Efficacy increase (from
86 to 98%) against IVM-
resistant H. contortus
[116]
ABZ, albendazole; ABZSO, active ABZ suphoxide metabolite; FLBZ, flubendazole; OFZ, oxfendazole; IVM, ivermectin;
MXD, moxidectin; AUC, area under the concentration versus time curve (systemic exposure). NA: no data available.benzimidazole efficacy. Thus, in vivo interference with hepatic FMO-mediated and/or CYP-
dependent metabolism has resulted in pronounced modifications to the pharmacokinetic
disposition and/or enhanced systematic availability of active benzimidazole molecules
[6,11]. Moreover, improved efficacy against benzimidazole-resistant strains of Teladorsagia668 Trends in Parasitology, August 2018, Vol. 34, No. 8
circumcincta and Haemonchus contortus has been shown after administration of fenbendazole
with piperonyl butoxide (a CYP inhibitor) in sheep [12]. These observations clearly pointed out
the practical relevance of interference with liver oxidative metabolism (Box 3), which may
represent a useful tool to increase the efficacy of benzimidazole anthelmintics.
Genomic and transcriptomic studies revealed the expression of xenobiotic-metabolizing
enzymes and drug-transport proteins within certain helminths such as H. contortus [13]
and Fasciola hepatica [14]. Metabolism enzymes and transporters act as parasite defense
mechanisms against ‘environmental’ chemical toxins generated by the host, and also protect
them from their own waste metabolic products. Further, biochemical studies with subcellular
fractions revealed that helminth parasites are able to metabolize certain benzimidazoles, such
as flubendazole [15], albendazole [16], and triclabendazole [17]. In addition, it has been
suggested that increased S-oxidation of albendazole in H. contortus [16] and triclabendazole
in F. hepatica [17,18] may contribute to the overall resistance mechanism toward these
anthelmintics. Thus, metabolic inhibitors may also decrease the rate of biotransformation of
these drugs within parasites and could help to improve drug activity, as shown after coincu-
bation of triclabendazole with metabolic inhibitors, such as methimazole [19], piperonyl but-
oxide [20], and ketoconazole [21].
Modulation of Drug-Transport-Mediated Excretion
The ATP-binding cassette (ABC) transporters use the energy of ATP hydrolysis to transport a
wide variety of substrates out of cells against a concentration gradient, leading to a decreased
intracellular concentration [22]. An important number of compounds extensively used in
ruminant species are substrates and/or inhibitors of different efflux ABC transporters [23].
Those interactions are now considered as a key pharmacological issue with multiple thera-
peutic implications. P-glycoprotein (P-gp; see ‘drug-transport proteins’ in the glossary) has
been the most studied cell transporter. Several in vivo and in vitro trials have been performed to
assess the interaction of macrocyclic lactones and P-gp modulators [24,25].
The majority of studies on drug interactions mediated by ABC transporters have been
addressed to modulate their activity, that is, increase absorption or delay the elimination ofBox 3. Modulation of Drug Metabolism and Transport-Mediated Excretion as Strategies to Optimize Anthelmintic Activity
Inhibitors of drug-metabolizing enzymes or transport proteins are useful pharmacological tools to increase the systemic exposure and efficacy of anthelmintic drugs.
Increased susceptibility of resistant parasites could be expected as a consequence of enhanced levels of active anthelmintic molecules attained in host tissues and
accumulated within target parasites. Different studies on the inhibition of the metabolism of the flukicidal triclabendazole and modulation of ivermectin excretion
(Figure I) are powerful examples of this research area.
In vitro studies with sheep liver microsomes showed that both the FMO and CYP systems are involved in the S-oxidation of triclabendazole [8]. In addition, subcellular
fractions of Fasciola hepatica were able to S-oxidize triclabendazole into its sulphoxide derivative, and this metabolic reaction was increased in resistant flukes [17].
Further in vitro assays revealed that different enzyme inhibitors (methimazole, piperonyl butoxide, ketoconazole) are able to delay triclabendazole metabolism in the
host [8] as well as in F. hepatica subcellular fractions from both susceptible and resistant strains [17]. Pharmacokinetic trials showed increased systemic exposure of
triclabendazole metabolites in sheep upon coadministration of the flukicidal drug with CYP inhibitors (piperonyl butoxide and ketoconazole) [11] (Figure I).
Furthermore, morphologic studies have shown that coincubation of triclabendazole or its sulphoxide metabolite with metabolic inhibitors leads to greater disruption
to tegument in triclabendazole-resistant flukes compared to that observed after adult fluke incubation with each anthelmintic molecule alone [19–21].
In vitro studies have demonstrated that P-gp plays a pivotal role in ivermectin elimination from ruminant hosts [119–121]. Moreover, overexpression of at least one P-
gp isotype has been suggested as one of the mechanisms involved in ivermectin resistance in nematodes such as Haemonchus spp. [37,40,92,122], Teladorsagia
circumcincta [40], and Cooperia oncophora [33]. In addition, P-gp inhibitors enhanced the in vitro activity of ivermectin against resistant larvae of those nematodes
[33,92] (Figure I). Different in vivo trials have shown increased ivermectin systemic exposure after its coadministration with P-gp-modulating agents such as verapamil
[26], quercetin [91], loperamide [43], and itraconazole [28]. Similarly, increased efficacies against resistant Haemonchus contortus and Trichostrongylus colubriformis
(sheep) and Cooperia spp. (cattle) were observed when the P-gp substrate loperamide was coadministered with ivermectin [43]. Loperamide (an opiod derivative)
induced relevant changes to the disposition kinetics of ivermectin in both species, enhancing their systemic exposure.
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Triclabendazole
Host liver (in vitro) 
Fasciola hepa?ca (in vitro)
TCBZ TCBZSO TCBZSO2
FMO (major)
CYP (minor)
FMO
CYP
Methimazole
(-) (-)
Piperonyl-butoxide
ketoconazole
(-) (-)
TCBZ TCBZSO
FMO?
CYP?
Methimazole
(-)
Piperonyl-butoxide
ketoconazole
(-)
• Evidence of FMO- and CYP-
   dependent S-oxidaƟon (not
   conclusive).
Host (in vivo) CYP inhibitors
• Delayed metabolism towards
   TCBZSO and TCBZSO2.
• Extended Ɵme of metabolite
   formaƟon.
• Increased systemic exposure
   of TCBZ metabolites
TCBZ alone
TCBZ + ketoconazole
TCBZ + piperonyl-butoxide
Effect of modulaƟon
• In vitro and in vivo studies in rodents showed greater disrupƟon to tegument in
   triclabendazole-resistant flukes.
• No conclusive evidence of increased efficacy in ruminants.
IvermecƟn
Host cells and nematodes (in vitro)  
• Enhanced suscepƟbility of
   Haemonchus spp.,
  Teladorsagia circumcincta
  and Cooperia oncophora to
  IVM (larval feeding,
  developmental and
  migraƟon inhibiƟon
  assays).     
Host (in vivo)
P-gp inhibitors (e.g., loperamide)
• Delayed eliminaƟon and increased IVM
    systemic exposure.
IVM alone
IVM + loperamide
Effect of modulaƟon
• The co-administraƟon with  loperamide increased IVM efficacy against resistant
   nematodes.  
• From a complete therapeuƟc IVM failure, the efficacy increased up to 73% 
   against H. contortus in the presence of the inhibitor (loperamide). 
IVM
• Present in host Ɵssues,
   parƟcularly in organs
   relevant to drug disposiƟon.
• Overexpressed in
    IVM-resistant
    parasites. 
IVM
P-gp interfering agents
reduce IVM efflux
P-gp mediated 
IVM efflux
Figure I. Illustrative Scheme of the Inhibition of Drug-Metabolizing Enzymes and Transport Proteins as Pharmacological Tools to Increase
Anthelmintic Activity. Both FMO and CYP enzyme systems are able to metabolize the flukicidal compound triclabendazole in the animal host liver. Adult Fasciola
hepatica specimens are also able to metabolize triclabendazole (left hand side of the figure). Moreover, triclabendazole-resistant liver flukes are more efficient at
biotransforming this anthelmintic drug compared to susceptible ones. Inhibition of both FMO (by methimazole) and CYP (by piperonyl-butoxide or ketoconazole)
enzymatic systems alter triclabendazole metabolism in host liver as well as within the target fluke parasite. Improved systemic exposure of triclabendazole-related
metabolites and enhanced ex vivo and in vivo efficacies have been observed in the presence of metabolic inhibitors. The transport protein P-gp has a pivotal role in
ivermectin excretion from the host. Overexpression of at least one P-gp isotype is one of the mechanisms of nematode resistance to ivermectin (right hand side of the
figure). Modulation of P-gp-mediated efflux activity enhanced ivermectin’s effect against resistant strains of ruminant nematodes. Enhanced systemic exposure in the
host and improved efficacy against highly ivermectin-resistant nematodes was shown after coadministration of ivermectin and a P-gp inhibitor (loperamide) in both
sheep and cattle.anthelmintic molecules. Changes to disposition kinetics and enhanced systemic exposure for
ivermectin (IVM) and/or moxidectin have been shown after their coadministration with P-gp
modulators, verapamil [26], loperamide [27], itraconazole [28], and ketoconazole [29]. Interfer-
ence of Pgp-mediated drug excretion has also been shown following coadministration of two
anthelmintic compounds. Ivermectin systemic exposure was markedly increased after its
coadministration with triclabendazole (flukicidal) [30] and albendazole [31] in sheep.
The protein transporter P-gp has also been described in nematode parasites such as
H. contortus [32] and Cooperia spp. [33]. Evidence supporting the involvement of P-gp in
the genetic changes associated with resistance [34] and the identification of several P-gp
sequences in the H. contortus genome [35] are considered key issues in anthelmintic670 Trends in Parasitology, August 2018, Vol. 34, No. 8
resistance. Modification of the pattern of P-gp expression (i.e., ivermectin-induced upregula-
tion) was observed in resistant nematodes recovered from treated lambs [34,36]. Differential
drug affinities by P-gp were also established. Moxidectin has a lower effect on the inhibition of
P-gp transport than ivermectin [37,38], which may explain the slower rate of resistance
development to moxidectin compared to other avermectins in H. contortus [37,38]. Also, a
marked induction of P-gps was observed in parasites exposed to different drugs. Several P-gp
genes showed significantly higher transcription (up to 12-fold) in resistant H. contortus after 3 h
exposure to ivermectin and levamisole. The exposure to both drugs also increased the activity
of constitutive transport proteins in susceptible isolates [39].
Modulation of efflux transport (P-gp) accounts for enhanced drug exposure in the host.
However, transport-related drug–drug interactions in parasite tissues may contribute to
enhanced drug accumulation and efficacy in resistant worms. P-gp modulators (PSC833,
verapamil, ketoconazole, pluronic 85) enhanced the sensitivity of larvae to ivermectin [40].
Verapamil also increased in vitro ivermectin activity against susceptible and resistant isolates of
Cooperia spp. [33], and the third generation of P-gp modulators (tariquidar, zosuquidar,
elacridar) have been shown to synergistically increase sensitivity to ivermectin [41]. The impact
of in vivo modulation of drug transport on anthelmintic activity against field resistant nematodes
has been assessed (Box 3). Attempts to reverse resistance were performed using the opioid-
derivative loperamide, which altered the disposition kinetics of both ivermectin and moxidectin,
improving their therapeutic responses against resistant Cooperia spp. (cattle) [42] and tolerant
GI nematodes (sheep) [43]. Similarly, pluronic 85 drastically increased ivermectin efficacy
against resistant H. contortus [44].
There is sound scientific evidence that modulation of P-gp-mediated excretion activity
increases the systemic exposure of some anthelmintic drugs in the host. Additionally, this
drug–drug interaction may also decrease the P-gp-mediated efflux overexpressed in resistant
helminth parasites, which could explain the favourable therapeutic response against resistant
nematodes observed in field trials. Further investigation is needed to discover potent and
specific modulators that permit a reversion of the resistance mechanism in parasites without
toxicity in the host.
Combination of Anthelmintic Drugs from Different Chemical Groups
Pharmacological Rationale behind the Use of Drug Combinations
There is a long history of chemotherapeutic agents with similar spectrums and different modes
of action used in combination for treating the most dreadful diseases, including cancer [45],
bacterial [46] and viral [47] infections. The combination strategy has been successful in
achieving improved efficacy, decreased toxicity, and reduced development of drug resistance.
In ruminants, nematodicidal combinations can be used to delay resistance development, to
control specific dose-limiting species, and/or to manage existing field resistance [48,49]
(Figure 1). Available data demonstrate that the use of drug combinations, especially when
they are introduced before resistance to all active ingredients included in the combination
develops, will slow the development of resistance [49–53]. Several pharmaceutical formulations
combining either two or three chemical entities are available in the market in some countries.
Fixed products mainly combine molecules belonging to the benzimidazole, macrocyclic lac-
tones, or imidazothiazole chemical groups. Additionally, a novel spiroindole compound (der-
quantel) has been combined with abamectin for use in sheep. Monepantel, the most recently
introduced nematodicidal aminoacetonitrile derivative, is commercialized alone but its associ-
ation with abamectin is under current consideration.Trends in Parasitology, August 2018, Vol. 34, No. 8 671
Genetic variation within populations of GI nematodes is unexpectedly large [2]. It is important to
note that the higher the genetic diversity, the greater the likelihood that resistant alleles will be
present. The rationale behind using drug combinations is based on the fact that individual
worms may have a lower degree of resistance to a multiple component formulation (each
chemical with a different mode of action/resistance) compared to that observed when a single
anthelmintic molecule is used (Box 4). The resulting low number of surviving parasites with
resistant genotypes would be diluted into the nematode population in refugia, and the resistant
worms would take longer to become predominant. Modeling [52,54,55] and empirical [50,51]
studies indicate that combined treatments are still effective in slowing the development of
resistance even when the initial resistance to one component of the combination is high.
Furthermore, a model simulation [55] suggested that when fitness costs associated with
resistance increase, resistance develops more slowly. In the absence of an adequate level
of refugia, the use of combinations has the potential to select for development of multiple drug-
resistant nematodes, reducing the range of anthelmintic options [56]. If parasite populations
under refuge is high (contaminated pastures), animal reinfection will be also high and animal
performance will be negatively affected; therefore, the frequency of anthelmintic treatments
(selection pressure) will increase, favoring resistance development. Achieving a correct balance
among nematode populations in refuge, worm burdens in grazing animals, and their productive
performance is a complex challenge.
Pharmaco-Parasitological Assessment of the Combined Use of Anthelmintics in Ruminants
The occurrence of potential pharmacokinetic and/or pharmacodynamic interactions
between drug components highlights the need for deeper pharmacology research to identify
the advantages/disadvantages of the use of combined drug preparations for anthelmintic
control in livestock (Figure 1).
Pharmacokinetic Interactions
The relationship among active drug concentrations in the bloodstream, those attained in
parasite location tissues of the host, and their accumulation within target parasites (Box 1),Box 4. Rationale and Practical Advantages Derived from the Use of Combined Nematodicidal Treatments
Rationale
The ‘initial’ parasite populations are genetically diverse [2], which leads to variation in the response to anthelmintic drugs. Thus, anthelmintic treatments provide a
survival advantage for worms carrying resistance alleles [123]. The rationale for using combined anthelmintic treatments is illustrated in Figure I. The ‘initial’ population
includes parasites susceptible to drugs named A and B (green-colored worms), worms resistant to either drug A (purple worms), to drug B (blue worms) or, at a lower
frequency, to both anthelmintic drugs (red worms) (multiple resistant). Under this scenario, the use of combined treatments is supported by the fact that the only
resistant genotypes which may survive are those simultaneously carrying genes for resistance to all the active ingredients. Thus, the use of anthelmintic combinations
can slow the development of resistance [54]. Theoretically, worms resistant to drug A and those multiple resistant (to drugs A and B) will survive after treatment with
drug A, contributing to the next generation. A similar situation could be expected after treatment with drug B. However, when drugs A and B are used in combination,
worms surviving one of the compounds could be killed by the other, with only a low proportion of multiple resistant parasites surviving. Achieving the highest possible
efficacy is a powerful argument for using anthelmintic combinations; since fewer resistant parasites will survive treatment, the diluting effect with susceptible
unselected parasites in refugia will be greater, and thus the development of resistance may be slowed [124,125].
Practical
An example of potential advantages derived from the use of anthelmintics in combination on a commercial cattle farm is shown in Figure I. After a combined treatment
of ivermectin (IVM) + ricobendazole (RBZ), a therapeutic additive effect was observed, with overall anthelmintic efficacies of 48% (IVM alone), 94% (RBZ alone), and
98% (IVM + RBZ). Additionally, the excretion of eggs to the pasture was found to be much lower following the combined treatment. At day 15 post-treatment, the
highest number of excreted eggs was exhibited by the group treated with IVM (16 million), followed by the RBZ group (2 million), and finally the combined IVM + RBZ-
treated calves (0.6 million) [53]. Therefore, the use of the combination resulted in lower pasture contamination than the treatment with RBZ alone. Thus, the field
situation demonstrated that the combined treatment achieved the highest efficacy, minimizing pasture contamination with resistant surviving worms, and thus
favoring dilution with unselected genotypes. In fact, the development of anthelmintic resistance would be delayed.
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Combined anthelminƟc treatments. RaƟonale Assessment in the field situaƟon
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Figure I. Illustration of the Rationale behind the Use of Combined Anthelmintic Treatments. Data from a field trial assessment is shown on the right hand
side of the figure. The therapeutic response following the administration of ivermectin (IVM) and ricobendazole (RBZ) given both separately and coadministered to
calves parasitized with gastrointestinal nematodes resistant to IVM and susceptible to RBZ [53] is schematically illustrated. Excreted eggs1: Sum of eggs excreted per
day (day 15 post-treatment) by the 15 animals included in each experimental group.is now well established. Drug interactions occurring during absorption and metabolism/trans-
port/excretion processes may affect the anthelmintic response. Positive pharmacokinetic
interactions between combined nematodicidal drugs have been observed in lambs [31,57].
Although most combined treatments in cattle did not show the existence of drug pharmacoki-
netic interactions (Table 1), the oral coadministration of abamectin + levamisole [58] resulted in
greater abamectin availability in the animals. Preferably, the actives in the combination should
have similar persistence in the organism to ensure that they are both present together
throughout the duration of the treatment [56]. In contrast, if their disposition patterns are
different, one compound may be present and the other absent at a given time, which allows
some parasites that are resistant to one component to survive treatment, thereby increasing the
proportion of resistant parasites. However, this situation is not different from what would be
experienced when each constituent active is used alone. Assessment of both the positive and
negative (adverse) impacts of pharmacokinetic interactions occurring between combinedTrends in Parasitology, August 2018, Vol. 34, No. 8 673
Table 1. Summary of in vivo trials Assessing Anthelmintic Combined Treatments against Gastrointestinal Nematodes in Cattle
Anthelmintic
combination
Treatment Route Parasitological assessment Pharmacological assessment Refs
Observed
efficacya (%)
Expected
efficacyb (%)
PD interaction Systemic exposure expressed as AUC Cmax PK interaction
Alone Combination Alone Combination
ABA + LEVc ABA Oral 90.5 104.3 144.9 35.9 53.0 Positive
interaction
[58]
LEV Oral 96.2 n.d. n.d. n.d. n.d. n.d.
ABA + LEV Oral 99.6 99.6 Additive
IVM + RBZ IVM SC 48.0 348 390 46.3 47.9 No interaction [53]
RBZ SC 94.0 10.8 10.9 0.85 0.77 No interaction
IVM + RBZ SC 98.0 96.8 Additive
RBZ + LEV RBZ SC 96.0 8.20 10.1 0.64 0.84 No interaction [97]
LEV SC 99.0 7.66 9.07 1.43 1.51 No interaction
RBZ + LEV SC 100 99.9 Additive
MXD + LEVd MXD SC 74.3 n.d. n.d. n.d. n.d. n.d. [98]
LEV SC 79.3 n.d. n.d. n.d. n.d. n.d.
MXD + LEV SC 98.1 94.6 Additive?
MXD + RBZd MXD SC 74.3 n.d. n.d. n.d. n.d. n.d. [98]
RBZ SC 37.5 n.d. n.d. n.d. n.d. n.d.
MXD + RBZ SC 88.4 83.9 Additive?
RBZ + CLOd RBZ SC 37.5 n.d. n.d. n.d. n.d. n.d. [98]
CLO Oral 49.6 n.d. n.d. n.d. n.d. n.d.
RBZ + CLO SC + Oral 60.2 68.5 Indifference
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Table 1. (continued)
Anthelmintic
combination
Treatment Route Parasitological assessment Pharmacological assessment Refs
Observed
efficacya (%)
Expected
efficacyb (%)
PD interaction Systemic exposure expressed as AUC Cmax PK interaction
Alone Combination Alone Combination
DRM + CLOd DRM SC 6.72 n.d. n.d. n.d. n.d. n.d. [98]
CLO Oral 49.6 n.d. n.d. n.d. n.d. n.d.
DRM + CLO SC + Oral 65.5 52.9 Synergism?
DRM + FBZd DRM SC 6.72 n.d. n.d. n.d. n.d. n.d. [98]
FBZ Oral 89.2 n.d. n.d. n.d. n.d. n.d.
DRM + FBZ SC + Oral 92.1 89.9 Additive
LEV + CLOd LEV SC 79.3 n.d. n.d. n.d. n.d. n.d. [98]
CLO Oral 49.6 n.d. n.d. n.d. n.d. n.d.
DRM + CLO SC + Oral 88.6 89.5 Additive
ABA, abamectin; LEV, levamisole; IVM, ivermectin; RBZ, ricobendazole; MXD, moxidectin; CLO, closantel; DRM, doramectin; FBZ, fenbendazole; SC, subcutaneous; PD, pharmacodynamic; PK,
pharmacokinetic; AUC, area under the plasma concentration versus time curve (expressed as either mgh/ml or ng.d/ml); Cmax, peak plasma concentration (expressed as mg/ml or ng/ml). n.d.: not
determined.
aObserved anthelmintic efficacy of the different treatments assessed by the faecal egg count reduction test.
bExpected efficacy assuming additive anthelmintic effects [49].
cThe results of the observed efficacy are presented as the mean across the ten farms included in the trial.
dThe results of the observed efficacy are presented as the mean across the four farms included in the trial.
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anthelmintic molecules needs to be elucidated before recommending the use of nematodicidal
drugs in combination.
Pharmacodynamic Interactions
The differential mode of actions exhibited by benzimidazoles, macrocyclic lactones and
imidazothiazoles may potentially induce a synergistic effect when they are coadministered.
Several in vitro studies demonstrated the synergistic activity of different nematodicidal drugs
used in combination [59,60]. Evidence of synergist action has been also observed under in vivo
conditions, where fenbendazole and levamisole were coadministered in goats parasitized with
resistant GI nematodes [61]. Production benefits for cattle parasitized with resistant nematodes
have been obtained with the combined use of doramectin and albendazole [62]. However,
most cases of in vivo pharmacodynamic interactions between nematodicidal drugs appear to
be limited to an additive effect both in sheep [63–65] and cattle (Table 1).
It is always important to note that a combination product may promote multidrug resistance if its
component drugs act on the same parasite gene or share a common resistance mechanism. In
fact, recent work suggests that resistance to IVM can be selected by previous exposure to
benzimidazole anthelmintics. It was hypothesized that genetic mechanisms related to benz-
imidazole resistance could also contribute to P-gp overexpression leading to IVM resistance
[66]. However, it is still unclear if this ‘cross resistance’ is sufficient to nullify the benefits of
administering these anthelmintics in combination.
The use of combinations in resistance management is not a panacea. Sustainable parasite
control should be customized to individual farms through the design of sound parasite-control
practices for each specific farm according to in situ obtained parasitological information.
Following those critical premises, nematodicidal combinations may remain as a sustainable
tool for parasite control in livestock.
Bioactive Natural Products: Assessment of Their Potential for Combined
Use with Anthelmintic Drugs
Anthelmintically Active Phytochemicals
Plants produce a variety of substances known as secondary metabolites, which play an
important role in plant defense mechanisms [67]. The bioactive phytochemical terpenes,
condensed tannins, and flavonoids are plant secondary metabolites with well established
anthelmintic properties and a growing relevance in ruminants’ helminth control.
Terpenes are structurally diverse and the most abundant group of plant volatiles. Terpenes are
present in different plant organs and are used to treat several human and animal diseases.
These bioactive compounds are synthesized as essential oils, which is a blend of different
terpenes, mainly monoterpenes [68,69]. The essential oils and their monoterpenes exhibit
notable anthelmintic properties both in vitro [70,71] and in vivo [70,72,73]. Chicory-based diets
(rich in sesquiterpene lactones) induced significant reductions in Ostertagia ostertagi worm
burdens in cattle [74,75]. There is limited information on the nematodicidal activity of mono-
terpenes in combination with other natural or synthetic compounds. However, there are several
studies reporting promising results for the combination of natural and synthetic compounds in
the control of fungi, bacteria, and ticks [76,77]. It has been proposed that inhibition of
biochemical targets such as acetylcholinesterase [78], GABA [79], and tyramine receptors
[80] may account for the anthelmintic action of terpenes. Terpenes also interact with glutamate-
gated chloride channels [81] and P-gp [82]. However, although several potential mechanisms676 Trends in Parasitology, August 2018, Vol. 34, No. 8
of action have been investigated, the specific mechanism supporting their anthelmintic activity
is still unknown.
Both the anthelmintic and nutritional effects of condensed tannins vary according to a number
of factors, including their concentration and chemical structures, physiological state, diet of the
ruminant host, and target GI nematodes [83]. Condensed tannins may act directly on nem-
atodes (anthelmintic effect) or indirectly by improving the nutritional status and host's immune
response against infection [84]. The direct anthelmintic action is based on the formation of
tannin–protein complexes. The cuticle and excretion/secretion products of different parasitic
life stages contain a variety of proteins. The tannin–nematode protein complexes may alter
some mechanisms necessary for parasite survival (L3 cuticle lost, feeding, motility, fecundity,
egg hatching, and a range of enzymatic-mediated biochemical functions) [83,85–87]. The most
effective immunological responses against infections occur due to a greater availability of
proteins to the host caused by the bypass effect, in which proteins bound to tannins are not
degraded in the rumen, increasing the rate of digestibility and protein degradation at the gut
level [88].
Plant flavonoids are a class of widely distributed phenolic compounds [89]. Flavonoids are P-gp
modulators with high in vitro activity against H. contortus [24,90]. The identification of natural
compounds that could either modulate drug efflux from the parasite or serve as synergists to
potentiate the activity of synthetic anthelmintics is an attractive challenge for research. Results
obtained from plant extracts rich in flavonoids are extremely encouraging either for potential
development of new compounds or to identify modulator agents capable of extending the
lifespan of existing anthelmintics [91,92].
Bioactive Phytochemicals as Tools to Complement Current Anthelmintic Therapy
The search for alternatives to the traditional anthelmintics requires urgent attention. The
identification of natural bioactives with potential to be used as complementary anthelmintic
tools is challenging [5]. The combined use of bioactive monoterpenes with synthetic anthel-
mintics may be optimal to achieve synergist activity at different sites of action [93]. Potential
additive or synergistic effects between natural and synthetic compounds should be more
fully evaluated against resistant worms. Synergism between monoterpenes and anthelmin-
tics has been demonstrated [79]. However, further work is needed to determine potential
kinetic/dynamic interferences between natural bioactives and the drugs to be combined
(Figure 1).
Taninipherous plants are available to ruminants in nature as, hay, pellets, etc. Tannins have the
ability to complex with several molecules, which could either reduce the GI absorption of
synthetic anthelmintics, decreasing their systemic availability and efficacy [94], or enhance
anthelmintic activity through the inhibition of detoxifying enzymes [85,87] (Figure 1). Evidence
has also shown that the association of flavonoids with condensed tannins [95], moxidectin [91],
or ivermectin [92] reaches a synergistic effect of great pharmacological relevance. However,
conclusive in vivo experiments showing beneficial efficacy after the combination of flavonoids
and ivermectin/moxidectin are not yet available. A cautious pharmacological assessment
should be performed to take full advantage of the control strategy based on either the use
of phytochemicals alone [96] or their combined administration with existing/novel anthelmintics
(Figure 1, Key Figure).
A huge challenge to increasing reliance on non-traditional means of parasite control is the high
cost of achieving a standardized natural product. However, the well-demonstrated synergisticTrends in Parasitology, August 2018, Vol. 34, No. 8 677
Key Figure
Schematic Representation of the Main Available Strategies to Increase Drug Activity against
Resistant Helminth Parasites in Ruminants (reviewed in the text)
Strategies to opƟmize the use of tradiƟonal and novel anthelminƟc compounds
Enhanced parasite
exposure
AlternaƟve/different
sites/modes of acƟon
SynergisƟc acƟvity acƟng at
different sites/modes of acƟon
   The pharmacokineƟc-based enhancement of parasite exposure has been
invesƟgated as a main pharmacological tool to opƟmize drug acƟvity against
resistant parasites.
   Enhanced systemic exposure results in increased drug concentraƟons
within target worms carrying resistant genes.
   Increased drug exposure may be a useful strategy for killing heterozygous
resistant worms during the earliest phases of resistance development.
However, no therapeuƟc advantage may be obtained when homozygous
resistant genotypes are predominant within the parasite populaƟon.
   The combinaƟon of two (or more) syntheƟc anthelminƟc drugs with
different sites/modes of acƟon/resistance is a useful pharmacological tool
when resistant nematodes are present.
   Individual worms may have a lower degree of resistance to a mulƟple
component (combined) formulaƟon compared to that observed aŌer the
use of a single anthelminƟc acƟve ingredient.
   AnthelminƟc combinaƟons can be used for delaying the appearance of
resistance, for specific targeƟng of dose-limiƟng species and/or for
management of exisƟng resistance.
   The use of bioacƟve natural products as complementary tools to exisƟng
syntheƟc anthelminƟc drugs has shown promising results (i.e., synergist
anthelminƟc acƟvity of terpenes with albendazole and/or ivermecƟn).
   Changes in anthelminƟcs systemic availability: (a) tannin-induced decrease
in gastrointesƟnal absorpƟon (ivermecƟn reduced exposure), (b) flavonoid-
induced metabolic interference (benzimidazole enhanced exposure).
   Further work is required to assess: (a) drug/bioacƟve phytochemical
combined efficacy responses, (b) mode of anthelminƟc acƟon and basis of
the synergist acƟvity, (c) chemical interacƟons affecƟng drug
absorpƟon/metabolism/excreƟon, (d) development of alternaƟve
formulaƟons/routes of administraƟon, (e) in vivo efficacy tesƟng.
1. PharmacokineƟc
opƟmizaƟon
2. CombinaƟon of different
chemical groups
3. Combined use of
syntheƟc anthelminƟcs and
bioacƟve phytochemicals
Figure 1. These strategies are based on either: (1) enhanced parasite exposure to the active ingredient, (2) simultaneous targeting at more than one site of action, or (3)
achieving synergistic activity at different sites of action after the combined use of a synthetic anthelmintic drug and bioactive natural products. Key explanatory
comments are shown on the right hand side of the scheme.effects occurring between certain natural and synthetic compounds may allow for the use of
lower concentrations and/or increase the efficiency of synthetic anthelmintics in resistant
populations. Any type of chemical combination should always be guided by a deep pharma-
cological understanding of the underlying mechanisms in order to optimize its therapeutic use
to control resistant nematodes.678 Trends in Parasitology, August 2018, Vol. 34, No. 8
Outstanding Questions
Valid strategies to improve parasite
control in livestock animals (enhanced
drug exposure, drug combinations,
bioactive natural products) have been
identified. Could these experimentally
observed therapeutic benefits be
transferred into sustainable parasite
control under field conditions? What
will be their ‘best’ or ‘more rationale’
use to be introduced into control
programs?
How can the favorable anthelmintic
synergistic effects of drug combina-
tions be optimized at the farm level?
What would be a reasonable rotation
scheme to extend the lifespan of these
advantageous drug mixtures?
Phytochemicals offer a relevant oppor-
tunity for parasite control in livestock.
How should they be used? As single
natural products or combined with
available anthelmintic drugs? If so,
what will be the risk of pharmaco-
chemical interactions affecting their
anthelmintic therapeutic response?
Suitable research strategies have been
identified as alternative measures of
parasite control (selection of resistant
animals, vaccine development, inte-Concluding Remarks
Anthelmintic resistance in animal-pathogenic helminths has been spreading in prevalence and
severity. Considering the increasing development of anthelmintic resistance, the use of phar-
macology-based information is critical to design successful strategies for future livestock
parasite control. Different pharmacokinetic-based approaches to enhance parasite exposure,
and the use of combinations of drugs from different chemical families, have been proposed as
valid strategies to delay the development of anthelmintic resistance (Figure 1). The activity of the
recently developed anthelmintics (i.e., monepantel, derquantel) against multidrug-resistant
isolates, which is based on novel modes of action, is a highly favorable element. However,
the integrated use of pharmacology-based information for both existing and novel molecules is
critical for the design of successful strategies for the future of parasite control. Modern
technologies will likely contribute with some leading products in the field of diagnostic or drug
discovery. Meanwhile, further pharmaco-parasitological integrated work, supported by signifi-
cant advances made in parasite genomics (see Outstanding Questions) is required to generate
the basic scientific knowledge necessary to optimize drug action and to preserve active
ingredients as useful and sustainable tools for parasite control in livestock animals. The
identification/development of complementary/alternative measures of parasite control in live-
stock animals is also required.
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